IONS * logo

Ionis Pharmaceuticals, Inc.BMV:IONS * Stock Report

Market Cap Mex$232.4b
Share Price
Mex$1.15k
Mex$1.27k
9.6% undervalued intrinsic discount
1Yn/a
7D0%
Portfolio Value
​
View

Ionis Pharmaceuticals, Inc.

BMV:IONS * Stock Report

Market Cap: Mex$232.4b

Ionis Pharmaceuticals (IONS *) Stock Overview

A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. More details

IONS * fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 37.1% below our estimate of its fair value

Earnings are forecast to grow 55.41% per year

Risk Analysis

Shares are highly illiquid


IONS * Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
UNCY logo
UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
View narrative
Community Contributor
US$21.53FV • 66.1% undervalued intrinsic discount
5419.8%Revenue growth p.a.
6.1k
18
0
121
3mo ago

Ionis Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ionis Pharmaceuticals
Historical stock prices
Current Share PriceUS$1,150.00
52 Week HighUS$1,180.00
52 Week LowUS$619.00
Beta0.30
1 Month Change0%
3 Month Change4.55%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-15.09%

Recent News & Updates

Recent updates

Shareholder Returns

IONS *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how IONS * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how IONS * performed against the MX Market.

Price Volatility

Is IONS *'s price volatile compared to industry and market?
IONS * volatility
IONS * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: IONS *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine IONS *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19891,069Brett Moniawww.ionis.com

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy.

Ionis Pharmaceuticals, Inc. Fundamentals Summary

How do Ionis Pharmaceuticals's earnings and revenue compare to its market cap?
IONS * fundamental statistics
Market capMex$232.41b
Earnings (TTM)-Mex$4.62b
Revenue (TTM)Mex$17.44b
13.3x
P/S Ratio
-50.3x
P/E Ratio

Is IONS * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IONS * income statement (TTM)
RevenueUS$966.96m
Cost of RevenueUS$893.25m
Gross ProfitUS$73.71m
Other ExpensesUS$330.05m
Earnings-US$256.34m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin7.62%
Net Profit Margin-26.51%
Debt/Equity Ratio290.8%

How did IONS * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/22 06:08
End of Day Share Price 2025/09/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ionis Pharmaceuticals, Inc. is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBarclays
Eliana MerleBarclays
Huidong WangBarclays